Thu, March 2, 2023
Wed, March 1, 2023
Tue, February 28, 2023

Matthew Harrison Upgraded (SRPT) to Buy and Increased Target to $187 on, Mar 1st, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-increased-target-to-187-on-mar-1st-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy and Increased Target from $141 to $187 on, Mar 1st, 2023.

Matthew has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Matthew


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $160 on, Tuesday, February 28th, 2023
  • Joseph Schwartz of "SVB Leerink" Reiterated at Buy and Held Target at $160 on, Friday, January 20th, 2023
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
  • Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022

Publication Contributing Sources